Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli
- PMID: 2457907
- PMCID: PMC281923
- DOI: 10.1073/pnas.85.16.6152
Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli
Erratum in
- Proc Natl Acad Sci U S A 1989 Feb;86(4):1387
Abstract
Epitopes for antibodies that inhibit factor VIII procoagulant protein were analyzed by deletion mapping of factor VIII protein fragments expressed in Escherichia coli. A human factor VIII cDNA clone was used to generate E. coli expression vectors encoding fragments containing the 80-kDa factor VIII light chain (A3, C1, and C2 domains) and the 44-kDa carboxyl-terminal half of the factor VIII heavy chain (A2 domain). A series of deletions of each fragment was constructed and tested by immunoblotting for the binding of alloantibody and autoantibody inhibitors. Analysis of derivatives of the 80-kDa fragment showed that six inhibitors recognized a major epitope(s) within the carboxyl-terminal 17.3 kDa of factor VIII. These inhibitors also recognized weaker epitopes nearby and one inhibitor recognized epitopes scattered throughout the 80-kDa fragment. Deletions within the heavy chain fragment revealed one epitope-containing region confined to the amino-terminal 18.3 kDa recognized by six inhibitors. Bacterially produced factor VIII fragments containing the major epitopes were capable of neutralizing inhibitors in vitro but fragments containing weaker or no epitopes did not. These data suggest a potential therapeutic use of factor VIII fragments for neutralization of inhibitor antibodies.
Similar articles
-
Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.Blood. 1989 Oct;74(5):1618-26. Blood. 1989. PMID: 2477082
-
A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.Thromb Haemost. 1993 Mar 1;69(3):240-6. Thromb Haemost. 1993. PMID: 7682339
-
Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide.Blood Coagul Fibrinolysis. 1992 Dec;3(6):703-16. doi: 10.1097/00001721-199212000-00002. Blood Coagul Fibrinolysis. 1992. PMID: 1283342
-
Molecular characterization of the immune response to factor VIII.Vox Sang. 2002 Aug;83 Suppl 1:403-8. doi: 10.1111/j.1423-0410.2002.tb05342.x. Vox Sang. 2002. PMID: 12617176 Review.
-
Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII.Semin Thromb Hemost. 2000;26(2):143-50. doi: 10.1055/s-2000-9816. Semin Thromb Hemost. 2000. PMID: 10919406 Review.
Cited by
-
Inhibition of human factor VIIIa by anti-A2 subunit antibodies.J Clin Invest. 1994 Jun;93(6):2497-504. doi: 10.1172/JCI117259. J Clin Invest. 1994. PMID: 8200986 Free PMC article.
-
Characterization of factor VIII inhibitors.Int J Hematol. 2006 Feb;83(2):109-18. doi: 10.1532/IJH97.05160. Int J Hematol. 2006. PMID: 16513528 Review.
-
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15. Haemophilia. 2018. PMID: 29446525 Free PMC article. Review.
-
Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen-Bethesda assay.Res Pract Thromb Haemost. 2022 Dec 12;6(8):e12799. doi: 10.1002/rth2.12799. eCollection 2022 Nov. Res Pract Thromb Haemost. 2022. PMID: 36518189 Free PMC article.
-
B-cell and T-cell epitopes in anti-factor VIII immune responses.Clin Rev Allergy Immunol. 2009 Oct;37(2):80-95. doi: 10.1007/s12016-009-8120-7. Clin Rev Allergy Immunol. 2009. PMID: 19184559 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous